CBU
DNTH icon

CIBC Bancorp USA’s Dianthus Therapeutics DNTH Stock Holding History

CIBC Bancorp USA’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$258K Buy
+2,646
New +$231K ﹤0.01% 1631

Other funds holding DNTH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

CIBC Bancorp USA's DNTH Position: Q2 2026 in Review

CIBC Bancorp USA opened a new position in Dianthus Therapeutics (DNTH) in Q2 2026: 2,646 shares worth $258K. The stake represents ﹤0.01% of the portfolio and ranks #1631 among its holdings.

244 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • CIBC Bancorp USA held 2,646 shares of Dianthus Therapeutics worth $258K as of Q2 2026.
  • Dianthus Therapeutics was a new CIBC Bancorp USA position in Q2 2026.
  • Dianthus Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1631 holding.
  • 244 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.